Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks.
在市场动荡和不确定时期，即使市场处于历史最高水平，许多投资者也会转向具备股息收益的股票。
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
在市场动荡和不确定的时期，许多投资者会转向股息收益股，这些通常是具有较高的自由现金流并以高红利派息奖励股东的公司。
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Benzinga的读者可以查看我们的分析师股票评级页面，查看最新的分析师对他们最喜爱的股票的看法。交易员可以浏览Benzinga的广泛分析师评级数据库，包括按分析师准确性排序。
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
以下是医疗保健板块三只高收益股票最准确的分析师评级。
Gilead Sciences, Inc. (NASDAQ:GILD)
吉利德科学股份有限公司（纳斯达克股票代码：GILD）
- Dividend Yield: 4.00%
- Cantor Fitzgerald analyst Olivia Brayer maintained a Neutral rating and cut the price target from $75 to $70 on July 22. This analyst has an accuracy rate of 65%.
- RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating with a price target of $74 on July 1. This analyst has an accuracy rate of 69%.
- Recent News: On July 25, Gilead Sciences announced new 5-year data reinforcing Biktarvy as a long term HIV treatment.
- Benzinga Pro's real-time newsfeed alerted to latest GILD news
- 股息率：4.00%
- Cantor Fitzgerald的分析师奥利维亚·布雷耶（Olivia Brayer）维持了中立评级，并在7月22日将目标价从75美元下调至70美元。该分析师的准确率为65%。
- RBC Capital的分析师布莱恩·阿伯拉罕斯（Brian Abrahams）在7月1日重申了板块表现评级，并给出了74美元的目标价。该分析师的准确率为69%。
- 最新消息：吉利德科学公司在7月25日宣布了新的5年数据，进一步证实Biktarvy作为一种长期治疗HIV的疗法。
- Benzinga Pro的实时新闻提醒了最新的吉利德科学公司的消息。
Pfizer Inc. (NYSE:PFE)
辉瑞公司(NYSE:PFE)
- Dividend Yield: 5.46%
- Barclays analyst Carter Gould maintained an Equal-Weight rating and raised the price target from $28 to $30 on July 10. This analyst has an accuracy rate of 64%.
- Argus Research analyst David Toung downgraded the stock from Buy to Hold on March 22. This analyst has an accuracy rate of 68%.
- Recent News: Pfizer announced last week that the European Commission approved a conditional marketing authorization for DURVEQTIX, a gene therapy for severe and moderately severe hemophilia B in adults whom meet certain criteria.
- Benzinga Pro's charting tool helped identify the trend in PFE's stock.
- 股息收益率：5.46%。
- 巴克莱银行的分析师卡特·古尔德（Carter Gould）维持了股票均衡评级，并在7月10日将目标价从28美元上调至30美元。该分析师的准确率为64%。
- 雅运股份的分析师大卫·汤（David Toung）于3月22日将股票评级从买入下调至持有。该分析师的准确率为68%。
- 最新消息：辉瑞上周宣布，欧洲委员会已为DURVEQTI，一种用于符合某些标准的成年重度和中度血友病患者的基因疗法，批准了有条件的营销授权。
- Benzinga Pro的绘图工具帮助识别了辉瑞股票的趋势。
Bristol-Myers Squibb Company (NYSE:BMY)
施贵宝公司（纽交所股票代号：BMY）
- Dividend Yield: 4.76%
- Deutsche Bank analyst James Shin maintained a Hold rating and cut the price target from $53 to $45 on July 23. This analyst has an accuracy rate of 73%.
- Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $51 to $52 on April 18. This analyst has an accuracy rate of 77%.
- Recent News: On July 26, Bristol-Myers Squibb posted better-than-expected quarterly earnings.
- Benzinga Pro's signals feature notified of a potential breakout in BMY shares.
- 股息收益率：4.76%
- 德意志银行的分析师詹姆斯·辛（James Shin）维持了持有评级，并在7月23日将目标价从53美元下调至45美元。该分析师的准确率为73%。
- 富国银行的分析师莫希特·班萨尔（Mohit Bansal）维持了股票均衡评级，并将目标价从51美元上调至52美元。该分析师的准确率为77%。
- 最新消息：施贵宝公司在7月26日公布了超预期的季度业绩。
- Benzinga Pro的信号功能提示了施贵宝公司股票的潜在突破。
Read More:
阅读更多：
- Jim Cramer Is 'Mystified' By Five Below, Predicts CrowdStrike 'Is Going To Bottom Here'
- 吉姆·克莱默对five below感到困惑，预测crowdstrike将在此处触底。